New drug combo tested for Tough-to-Treat blood disorder
NCT ID NCT03359460
Summary
This small, early-stage study aimed to find a safe dose for combining two existing drugs, ibrutinib and lenalidomide, to treat myelodysplastic syndrome (MDS). It involved patients whose MDS had not responded to or who could not tolerate standard treatments. The main goal was to check for side effects and determine the best dose for future research, with a secondary look at whether the combination showed any signs of helping control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California Davis Comprehensive Cancer Center
Sacramento, California, 95817, United States
Conditions
Explore the condition pages connected to this study.